Welcome to LookChem.com Sign In|Join Free
  • or
4-hydroxy-1-trityl-1H-pyrazole is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

226989-36-2

Post Buying Request

226989-36-2 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

226989-36-2 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 226989-36-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,2,6,9,8 and 9 respectively; the second part has 2 digits, 3 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 226989-36:
(8*2)+(7*2)+(6*6)+(5*9)+(4*8)+(3*9)+(2*3)+(1*6)=182
182 % 10 = 2
So 226989-36-2 is a valid CAS Registry Number.

226989-36-2Relevant academic research and scientific papers

5-(2-(2,5-DIFLUOROPHENYL)PYRROLIDIN-1 -YL)-3-(1H-PYRAZOL-1-YL)PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AND RELATED COMPOUNDS AS TRK KINASE INHIBITORS FOR TREATING CANCER

-

, (2019/07/19)

The application relates to pyrazolo[1,5-a]pyrimidine derivatives of formula (IV) as Trk kinase inhibitors for treating cancer and inflammatory diseases

A novel series of glucagon receptor antagonists with reduced molecular weight and lipophilicity

Filipski, Kevin J.,Bian, Jianwei,Ebner, David C.,Lee, Esther C.Y.,Li, Jian-Cheng,Sammons, Matthew F.,Wright, Stephen W.,Stevens, Benjamin D.,Didiuk, Mary T.,Tu, Meihua,Perreault, Christian,Brown, Janice,Atkinson, Karen,Tan, Beijing,Salatto, Christopher T.,Litchfield, John,Pfefferkorn, Jeffrey A.,Guzman-Perez, Angel

scheme or table, p. 415 - 420 (2012/02/16)

A novel series of glucagon receptor antagonists has been discovered. These pyrazole ethers and aminopyrazoles have lower molecular weight and increased polarity such that the molecules fall into better drug-like property space. This work has culminated in

Divergent synthesis and evaluation of inhibitory activities against cyclooxygenases-1 and -2 of natural withasomnines and analogues

Usami, Yoshihide,Watanabe, Ryo,Fujino, Yuiko,Shibano, Makio,Ishida, Chihiro,Yoneyama, Hiroki,Harusawa, Shinya,Ichikawa, Hayato

, p. 1550 - 1560 (2013/02/22)

The divergent synthesis of natural withasomnines and analogues was achieved from 4-hydroxypyrazoles, which was prepared via alkaline hydrolysis of the Baeyer-Villiger oxidation products from 4-formylpyrazoles. Key steps of this synthesis are regioselective Claisen rearrangement of 4-allyloxypyrazoles and the Suzuki-Miyaura coupling of 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl trifluoromethanesulfonate and commercially available arylboronic acids. The Suzuki-Miyaura coupling at the final step of this strategy enabled facile access to natural withasomnines and their analogues. The biological activities of the twelve synthesized compounds against cyclooxygenases-1 and -2 (COX-1 and COX-2) were evaluated.

Divergent synthesis of withasomnines via synthesis of 4-hydroxy-1H- pyrazoles and Claisen rearrangement of their 4-O-allylethers

Ichikawa, Hayato,Watanabe, Ryo,Fujino, Yuiko,Usami, Yoshihide

scheme or table, p. 4448 - 4451 (2011/09/19)

4-Hydroxypyrazoles were synthesized by the alkaline hydrolysis of the Baeyer-Villiger oxidation products of 4-formylpyrazoles. This new synthesis of 4-hydroxypyrazoles was applied to the divergent synthesis of withasomnine alkaloids in a unique strategy, for which the key steps included the regioselective Claisen rearrangement of their 4-O-allyl-4-hydroxy-1H-pyrazoles and a Suzuki coupling of 4-trifluoromethanesulfonyloxy-1H-pyrazoles and arylboronic acids.

SELECTIVE BETA3 ADRENERGIC AGONISTS

-

, (2019/06/28)

The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective β 3 receptor agonists useful in the treatment of Type II diabetes and obesity. The invention provides compounds and methods of treating Type II diabetes and obesity, comprising administering to a mammal in need thereof compounds of formula (I) or a pharmaceutically acceptable salt thereof. The variables of formula (I) have the meanings defined herein.

SELECTIVE BETA3 ADRENERGIC AGONISTS

-

, (2015/09/24)

The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective β 3 receptor agonists useful in the treatment of Type II diabetes and obesity. The invention provides compounds and methods of treating type II diabetes and obesity, comprising administering to a mammal in need thereof compounds of the Formula I:

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 226989-36-2